isarna-therapeutics.comHealthcareFounded: 1900Funding to Date: $131.24MM
Isarna Therapeutics is a clinical stage biotech company developing ISTH0036, a next-generation antisense to block TGF-beta 2 production, a key molecule in the pathogenesis of retinal disease.
For more details on financing and valuation for Isarna Therapeutics, register or login.
View Enterprise Value for Isarna Therapeutics.
To read this article and more news on Isarna Therapeutics, register or login.